Specifics of targeted antibiotic treatment in hematooncological patients

Abstract

Main contributors to mortality in hematooncology patients are progression of primary disease together with infections. These infections may be caused by atypical pathogens and very often present with much severe course than can be seen in otherwise healthy population.

Adequate therapy is mainstay to success in the treatment. Good susceptibility to antibiotics as well as correct dosing and organ penetration are the cornerstones of the treatment.

Keywords

• antibiotics
• hematooncology patient
• infection
• pharmacodynamics
• pharmacokinetics